Nanexa signs agreement with a European Biotech company for evaluation of PharmaShell®
Nanexa AB (publ) today announced that the company has signed an evaluation agreement, a so-called Material Transfer and Feasibility Study Agreement, with a non-disclosed European biotech company. The company is running a development project within the cardiovascular field, where PharmaShell®, as the drug delivery system, can enable an injectable product that releases the drug substance during 1-2 weeks.
“It is very exciting that this company, a new partner to us, sees the opportunity in our technology and now starts an evaluation of PharmaShell® for one of its development projects. We look forward to starting the work shortly and to generate results in the near future that can be the basis for a more extensive and long-term development agreement,” says David Westberg, CEO of Nanexa.
The agreement regulates, among other things, details of what shall be investigated, clarification regarding patent rights and a smaller determined fee to Nanexa for this evaluation.
